Journal of internal medicine
-
Randomized Controlled Trial
Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
We recently reported that the administration of zoledronate every 18 months to osteopenic older women reduces the incidence of fractures. ⋯ The present analyses indicate that the decrease in fracture numbers is broadly consistent across this cohort. The lack of relationship between NNTs and baseline fracture risk calls into question the need for BMD measurement and precise fracture risk assessment before initiating treatment in older postmenopausal women.